AstraZeneca PLC (AZN.LN) said Friday that its drug Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in Phase 3 Olympus and Rockies trials.
The drugmaker said the results of the global Phase 3 program as well as other data will form part of a regulatory submission in the U.S., which is anticipated in the fourth quarter of 2019.
Roxadustat is currently approved in China for the treatment of anemia in patients with CKD, regardless of whether they require dialysis, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.